Localized Steroid-Releasing Technology

Intersect ENT’s core technology is its bioabsorbable, sustained drug release platform. This advancement in ENT surgery improves patient care and is a cost effective option for preventing the need for postoperative interventions.1

PROPEL, PROPEL Mini and PROPEL Contour Chronic Sinusitis Implants
propel logo

Opens. Delivers. Maintains.

PROPEL sinus implants are the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue.

Inserted to maintain the surgical opening, the springlike implant is placed following surgery and expands to prop open the sinus and gradually deliver an advanced corticosteroid with anti-inflammatory properties directly to the sinus lining as the implant dissolves.

Steroid-Releasing Implants to Improve Sinus Surgery Outcomes

The PROPEL family of steroid-releasing implants may be used for patients post ethmoid, frontal or maxillary surgeries, which represents the majority of chronic sinusitis procedures.

Ethmoid

PROPEL Mometasone Furoate Chronic Sinusitis Implant Logo

Learn More

Ethmoid & Frontal

PROPEL Mini Mometasone Furoate Chronic Sinusitis Implant Logo

Learn More

Frontal & Maxillary

PROPEL Contour Mometasone Furoate Chronic Sinusitis Implant Logo

Learn More

Continuing the Innovation

We are working on new technologies to provide localized drug delivery to even more patients.

Learn More

1Rudmik L and Smith TL. Economic Evaluation of a Steroid-Eluting Sinus Implant following Endoscopic Sinus Surgery for Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2014 May 5; 151(2):359-366.

The PROPEL sinus implants are intended for use after sinus surgery to maintain patency and to locally deliver steroid to the sinus mucosa: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening, and PROPEL Contour for use in the frontal and maxillary sinus ostia. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implants in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For complete prescribing information see IFU at www.IntersectENT.com. Rx only.